Assessing food preferences to address undernutrition in stage IV lung cancer patients
Influence of Food Preferences on the Occurrence of Undernutrition in Treated Patients for Bronchopulmonary Carcinoma Non-small Cell Stage IV
This study is testing if personalized dietary help can improve food preferences and nutrition for patients with stage IV lung cancer who are starting treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 190 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Centre Georges Francois Leclerc Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Dijon, Côte d'Or) |
| Trial ID | NCT05496556 on ClinicalTrials.gov |
What this trial studies
This study focuses on patients diagnosed with stage IV non-small cell lung carcinoma who are receiving first-line treatment. Participants will undergo a comprehensive assessment that includes clinical exams, imaging, biological tests, and dietary consultations. If undernutrition is identified, patients will receive personalized dietary management tailored to their symptoms, treatment side effects, and social circumstances. Follow-up assessments will occur every 4 to 6 weeks until disease progression or other significant events occur.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 to 70 with stage IV non-small cell lung carcinoma receiving first-line treatment and fluent in French.
Not a fit: Patients requiring hospitalization for more than 48 hours or those with acute infections or significant psychiatric disorders may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could improve nutritional status and overall quality of life for patients with advanced lung cancer.
How similar studies have performed: While similar studies focusing on nutritional interventions in cancer patients have shown promise, this specific approach is novel in its integration of food preferences with dietary management.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of stage IV non-small cell lung carcinoma with indication for first-line systemic treatment (chemotherapy, immunotherapy or specific treatment, in particular tyrosine kinase inhibitors) according to current French recommendations. * Age over 18 and under 70 * Patient speaking and reading French fluently * Affiliation to a social security scheme * Patient able and willing to follow all study procedures in accordance with the protocol * Patient having understood, signed and dated the consent form Exclusion Criteria: * Patient requiring hospitalization for more than 48 hours for the administration of the first course of treatment * Patient benefiting from antibiotic therapy for the treatment of an acute infection * Psychiatric, cognitive or neurological disorders making it impossible to assess food preferences and/or any impossibility to undergo medical monitoring for the trial for geographical, social or psychological reasons. * Daily alcohol consumption * Chest radiotherapy treatment * Pregnant woman, likely to be, or breastfeeding * Persons deprived of liberty or under guardianship
Where this trial is running
Dijon, Côte d'Or
- Centre Georges-François Leclerc — Dijon, Côte d'Or, France (Recruiting)
Study contacts
- Study coordinator: Sophie rs BETTING
- Email: sbetting@cgfl.fr
- Phone: 0(3) 45 34 81 08
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.